Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Addressing bioenergetic deficits and restoring mitochondrial health in transplanted islets using mesenchymal stem cells.

Primavera R., Ganguly A., Yarani R., Bettencourt L., Regmi S., Chetty S.

Animal Study on Systemic / IV, published in Stem Cells Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cells Transl Med (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42367078
DOI
10.1093/stcltm/szag038

Abstract (original English)

During the process of islet transplantation, islets undergo isolation and are then introduced into a new microenvironment where they need to adapt and revascularize. This transition imposes substantial stress on islets, leading to mitochondrial dysfunction and oxidative stress, adversely affecting islet function and vitality. Mesenchymal stem cells (MSCs) offer a promising therapy to mitigate these adverse effects by restoring their bioenergetic capacity and overall functionality of islets. Our study investigates how human MSCs (hMSCs) from different sources-adipose tissue (AD), bone marrow (BM), and umbilical cord (UC)-can restore the bioenergetic capacity of inflamed pancreatic islets. We assess how hMSCs can improve islet survival, function, and mitochondrial health, by analyzing key mitochondrial oxidative stress-related genes. In addition, this study examines the functional effect of co-transplanting islets with hMSCs in vivo in diabetic mice. hMSCs, particularly those from UC and BM, can effectively sustain islet viability, enhance mitochondrial function, and alleviate oxidative stress, as evidenced by increased expression of key mitochondrial markers such as PPARGC1A, TOMM20, and Sod2. Furthermore, co-transplantation of hMSCs with sub-therapeutic islet numbers leads to long-term improvements in glucose regulation, with UC-hMSCs showing better short-term efficacy (100% of

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansMesenchymal Stem CellsIslets of Langerhans TransplantationMesenchymal Stem Cell TransplantationMitochondriaMiceIslets of LangerhansOxidative StressEnergy Metabolism

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research